Research

Research is of great important in the Bellevue clinics. Many of our doctors are involved and participate in different research project on various pathologies such as:

  • Glaucoma
  • Macular Degeneration
  • Diabetic retinopathy
  • And others

Here is a brief overview of the various research projects currently underway in the Bellevue clinics. You will also find on this page announcements when recruiting patients for future studies.

We will also present the findings and conclusions of previous research.

Enjoy your readings !

Current research projects

Hydrus V

A prospective, multicenter and randomized comparison of the Hydrus TM to the IStent in order to reduce intraocular pressure in primitive open angle glaucoma.

Goal: The goal of this study is to compare the new  Hydrus implant to the capacity of the Istent (standard implant) to reduce the pressure in the eye.

Rocket 3

A 12-month, randomized, double-blind, active-controlled, parallel-group, multicenter study to compare the safety of AR-13324 ophthalmic solution to 0.02% 1 fpd and 2 fpd with an ophthalmic solution of maleate Timolol 0.5% in patients with high intraocular pressure

Goal: The goal of this research study is to compare the safety of the ophthalmic solution AR13324 to 0.02% with that of an ophthalmic solution of 0.5% timolol maleate available on the market to lower intraocular pressure in patients with glaucoma Or ocular hypertension (increased ocular pressure).

Simbrinza study

Additive effect of the therapeutic combination of 1% brinzolamide and 0.2% fixed-dose brimonidine administered twice daily as an adjunct to a prostaglandin analogue

Goal: The goal of this research study is to demonstrate the ability of a fixed-dose therapeutic combination of SIMBRINZA ™ (1% brinzolamide and 0.2% brimonidine) to reduce intraocular pressure in research participants also treated with A prostaglandin analogue such as 0.004% TRAVATAN® (Travoprost), or 0.01% LUMIGAN® (Bimatoprost), or 0.005% XALATAN® (Latanoprost) with respect to the effect and capacity of treatment with an analogue of Prostaglandins used alone to reduce intraocular pressure.

Hydrus III

A randomized, prospective, and multi-center trial comparing the safety and efficacy of the Hydrus implant meant to reduce intraocular pressure in patients with glaucoma undergoing cataract surgery.

Goal : The goal of this study is to determine if a study device, the Hydrus IVANTIS implant, can be implanted safely in your eye and can reduce the pressure in your eye after cataract removal and An intraocular lens (IOL) has been implanted in your eye.

Bimatoprost SR

Efficacité et innocuité du bimatoprost à libération prolongée chez les patients atteints d’un glaucome à angle ouvert ou d’hypertension oculaire.

Goal: The purpose of this study was to examine the safety (safety of use) and efficacy of two different amounts (10 μg and 15 μg) of sustained-release bimatoprost compared to timolol-containing eye drops To 0.5% to reduce ocular pressure in patients with glaucoma or high ocular pressure. 0.5% timolol is an approved drug for lowering ocular pressure. The bimatoprost extended release is a very small implant, which is biodegradable (dissolves naturally in the body) and contains bimatoprost. The sustained release bimatoprost is placed inside a chamber of the eye (between the cornea [the transparent part of the eye] and the iris [the coloured part of the eye]).

Results of previous research projects

Coming soon.